Synthesis of the Alzheimer drug Posiphen into its primary metabolic products (+)-N(1)-norPosiphen, (+)-N(8)-norPosiphen and (+)-N(1), N(8)-bisnorPosiphen, their inhibition of amyloid precursor protein, α-synuclein synthesis, interleukin-1β, and cholinergic action

Documenti analoghi

• Amyloid precursor protein synthesis inhibitors for Alzheimer’s disease treatment
  di: Greig, Nigel H., et al.
  Pubblicazione: (2014)
• Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer’s disease
  di: Ray, Balmiki, et al.
  Pubblicazione: (2020)
• Correction: Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer’s disease
  di: Ray, Balmiki, et al.
  Pubblicazione: (2020)
• MicroRNA-339-5p Down-regulates Protein Expression of β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 (BACE1) in Human Primary Brain Cultures and Is Reduced in Brain Tissue Specimens of Alzheimer Disease Subjects
  di: Long, Justin M., et al.
  Pubblicazione: (2014)
• The alpha-synuclein 5(′)untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen
  di: Rogers, Jack T., et al.
  Pubblicazione: (2011)